Incannex Healthcare (IXHL) Stock Price, News & Analysis

Company Overview

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Key Stats

• Today's Range: $0.53 to $0.62
• 50-Day Range: $0.20 to $1.63
• 52-Week Range: $0.08 to $3.12
• Volume: 393.21 million shs
• Average Volume: 60.27 million shs
• Market Capitalization: $16.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Incannex Healthcare Stock Analysis - MarketRank™

Incannex Healthcare scored higher than 7% of companies evaluated by MarketBeat, and ranked 930th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Incannex Healthcare.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Incannex Healthcare is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Incannex Healthcare is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Incannex Healthcare has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.86% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Incannex Healthcare has recently increased by 82.53%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Incannex Healthcare does not currently pay a dividend.

Dividend Growth

Incannex Healthcare does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.86% of the float of Incannex Healthcare has been sold short.

Short Interest Ratio / Days to Cover

Incannex Healthcare has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Incannex Healthcare has recently increased by 82.53%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.04

News Sentiment

Incannex Healthcare has a news sentiment score of 0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Incannex Healthcare this week, compared to 1 article on an average week.

Search Interest

96 people have searched for IXHL on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.

MarketBeat Follows

26 people have added Incannex Healthcare to their MarketBeat watchlist in the last 30 days. This is an increase of 44% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Incannex Healthcare insiders have not sold or bought any company stock.

Percentage Held by Insiders

15.49% of the stock of Incannex Healthcare is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 0.43% of the stock of Incannex Healthcare is held by institutions.

IXHL Stock Analysis - Frequently Asked Questions

How have IXHL shares performed this year?

Incannex Healthcare's stock was trading at $2.12 at the beginning of the year. Since then, IXHL shares have decreased by 73.0% and is now trading at $0.5730.

How were Incannex Healthcare's earnings last quarter?

Incannex Healthcare Inc. (NASDAQ:IXHL) announced its earnings results on Thursday, May, 15th. The company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.22. The firm earned $0.10 million during the quarter, compared to analyst estimates of $0.16 million.

Who are Incannex Healthcare's major shareholders?

Incannex Healthcare's top institutional investors include AdvisorShares Investments LLC (1.17%).

How do I buy shares of Incannex Healthcare?

Shares of IXHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Incannex Healthcare own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Incannex Healthcare investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Disc Medicine (IRON) and Jabil (JBL).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 8/22/2025
• Next Earnings (Estimated): 9/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IXHL
• CIK: 1873875
• Web: impression.healthcare
• Phone: 425-703-805
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.21)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$18.46 million
• Net Margins: N/A
• Pretax Margin: -22,156.12%
• Return on Equity: -342.92%
• Return on Assets: -148.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.12
• Quick Ratio: 2.12

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,346.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 2.54

Miscellaneous

• Outstanding Shares: 29,430,000
• Free Float: 24,875,000
• Market Cap: $13.46 million
• Optionable: Not Optionable
• Beta: 7.67